Arcutis Biotherapeutics Inc
General ticker "ARQT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B
Arcutis Biotherapeutics Inc follows the US Stock Market performance with the rate: 46.8%.
Estimated limits based on current volatility of 5.1%: low 14.10$, high 15.61$
Factors to consider:
- Current price 183.8% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.71$, 5.27$]
- 2024-12-30 to 2025-12-30 estimated range: [1.87$, 4.99$]
Financial Metrics affecting the ARQT estimates:
- Negative: Non-GAAP EPS, $ of -3.92 <= 0.10
- Negative: Operating profit margin, % of -80.18 <= 1.03
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Operating cash flow per share per price, % of -60.77 <= 2.35
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Interest expense per share, $ of 0.43 <= 0.74
Short-term ARQT quotes
Long-term ARQT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $3.69MM | $59.61MM |
| Operating Expenses | $206.53MM | $305.31MM | $300.71MM |
| Operating Income | $-206.53MM | $-301.63MM | $-241.10MM |
| Non-Operating Income | $0.17MM | $-9.83MM | $-17.93MM |
| Interest Expense | $0.00MM | $9.83MM | $29.71MM |
| R&D Expense | $145.56MM | $182.44MM | $110.58MM |
| Income(Loss) | $-206.36MM | $-311.46MM | $-259.03MM |
| Taxes | $0.00MM | $0.00MM | $3.11MM |
| Profit(Loss) | $-206.36MM | $-311.46MM | $-262.14MM |
| Stockholders Equity | $297.68MM | $209.58MM | $88.67MM |
| Inventory | $1.18MM | $7.51MM | $13.13MM |
| Assets | $408.15MM | $449.27MM | $341.37MM |
| Operating Cash Flow | $-174.63MM | $-257.71MM | $-247.06MM |
| Capital expenditure | $0.99MM | $23.28MM | $0.43MM |
| Investing Cash Flow | $-75.95MM | $-87.20MM | $180.23MM |
| Financing Cash Flow | $281.95MM | $301.80MM | $101.32MM |
| Earnings Per Share* | $-4.17 | $-5.84 | $-3.78 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.